will tirzepatide be banned FDA confirms shortage is still over, gives compounders a grace period FDA moves to remove GLP-1
Description
Putting out what works to help others find their fit

This is the price for patients without insurance, with commercial insurance that does not cover Wegovy, or those who are self-paying/opting to process outside of their commercial insurance plan

The weight loss with semaglutide 2.4 mg weekly is impressive, with an average weight loss of 15% among participants at 68 weeks in STEP trials

GLP-1s are actually simpler in many wayssubcutaneous injection, predictable titration schedule, manageable side effect profile (mostly GI: nausea, occasional vomiting)

Each has a different reliability rate and susceptibility to false positives